High SLC20A1 Expression Indicates Poor Prognosis in Prostate Cancer

Taiki Okamoto; Chotaro Onaga; Izumi Matsuoka; Ayaka Ozaki; Chika Matsuda; Takahiro Kasai; Yuyun Xiong; Yohsuke Harada; Tsugumichi Sato; Yoshio Nakano; Yasunari Mano; Satoru Miyazaki; Hitoshi Ishiguro; Keiko Sato; Shoma Tamori; Kazunori Sasaki; Shigeo Ohno; Kazunori Akimoto

doi:10.21873/cdp.10237

High SLC20A1 Expression Indicates Poor Prognosis in Prostate Cancer

Cancer Diagn Progn. 2023 Jul 3;3(4):439-448. doi: 10.21873/cdp.10237. eCollection 2023 Jul-Aug.

Authors

Taiki Okamoto¹, Chotaro Onaga¹, Izumi Matsuoka¹, Ayaka Ozaki¹, Chika Matsuda¹, Takahiro Kasai¹, Yuyun Xiong¹, Yohsuke Harada¹, Tsugumichi Sato^{2

3}, Yoshio Nakano^{2

3}, Yasunari Mano^{2

3}, Satoru Miyazaki², Hitoshi Ishiguro^{4

5}, Keiko Sato^{3

6}, Shoma Tamori^{1

3}, Kazunori Sasaki⁷, Shigeo Ohno⁷, Kazunori Akimoto^{1

3}

Affiliations

¹ Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.
² Department of Pharmacy, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.
³ Research Division of Medical Data Science, Research Institute for Science and Technology, Tokyo University of Science, Chiba, Japan.
⁴ Department of Urology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
⁵ Life Science Technology Project, Research and Development Department, Kanagawa Institute of Industrial Science and Technology, Kanagawa, Japan.
⁶ Department of Information Sciences, Faculty of Science and Technology, Tokyo University of Science, Chiba, Japan.
⁷ Laboratory of Cancer Biology, Institute for Diseases of Old Age, Juntendo University School of Medicine, Tokyo, Japan.

Abstract

Background/aim: High expression of solute carrier family 20 member 1 (SLC20A1) indicates poor clinical outcomes for patients with breast cancer subtypes treated with endocrine therapy and radiotherapy. However, the association between SLC20A1 expression and clinical outcomes in prostate cancer remains to be determined.

Materials and methods: Open-source datasets (The Cancer Genome Atlas prostate, Stand Up to Cancer-Prostate Cancer Foundation Dream Team, and The Cancer Genome Atlas PanCancer Atlas) were downloaded and analyzed. SLC20A1 expression was analyzed in prostate cancer and normal prostate tissue. Survival analysis using Kaplan-Meier curves and Cox regression analysis were performed to examine patient prognosis, as well as the effects of endocrine therapy and radiotherapy on high SLC20A1 expression in patients with prostate cancer.

Results: SLC20A1 was higher in prostate cancer than in normal prostate tissues. High SLC20A1 expression predicted poor disease-free and progression-free survival. Following endocrine therapy, no significant difference in prognosis was observed between patients with high SLC20A1 and those with low SLC20A1 expression. However, following radiotherapy, high SLC20A1 expression tended to be associated with a poor clinical outcome.

Conclusion: SLC20A1 may serve as a prognostic biomarker for prostate cancer, and the recommended treatment for patients with high SLC20A1 expression is endocrine therapy.

Keywords: Prostate cancer; SLC20A1; prognostic marker.